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ABSTRACT	  HIV-1	  causes	  progressive	  neurological	  disorders	  collectively	  known	  as	  HIV-associated	  neurocognitive	  disorders	  (HAND).	  	  HAND	  is	  considered	  an	  umbrella	  term	  that	  encompasses	  three	  major	  stages:	  Asymptomatic	  neurocognitive	  impairment	  (ANI),	  mild/moderate	   neurocognitive	   disorder	   (MND),	   and	   HIV-associated	  dementia	  (HAD).	  The	  prevalence	  of	  HAND	  has	  increased	  despite	  the	  use	  of	  combined	  antiretroviral	  therapy	  (cART)	  and	  still	  affects	  20	  –	  40%	  of	  HIV-1	  infected	  individuals.	  The	  underlying	  cause	  of	   HAND	  observed	  in	  a	  particular	  set	  of	  subjects	  has	  not	  yet	  been	  fully	  elucidated	  nor	  have	  there	  been	  any	  ways	  to	  determine	  if	  an	  infected	  individual	  will	  eventually	  progress	  to	  HAND.	  Previously	  we	  have	  shown	  that	  Neurogranin	  (NRGN),	  is	  significantly	  downregulated	  in	  patients	  with	  high	  viral	  load	  at	  the	  mRNA	  level.	  NRGN	  is	  involved	  in	  the	  protein	  kinase	  C	  pathway	  and	  binds	  to	  calmodulin	  (CaM)	  and	  decreases	  the	  threshold	  for	  long-term	   potentiation	  (LTP),	  which	  is	  involved	  in	  learning	  and	  memory.	  	  We	  hypothesize	  that	  dysregulation	  of	  NRGN	  may	  be	  in	  part	  associated	  with	  development	  of	  HAND.	  To	  further	  understand	  the	  role	  of	  NRGN,	  we	  propose	  to	  delineate	  the	  role	  of	  NRGN	  and	  the	  mechanism(s)	  involved	  in	  HIV-1	  induced	  degradation	  of	  NRGN.	  	  
 The public health significance is in determining contributors to the degradation of 
cognition in HIV-1 infected individuals that progress to HAND, treatments can be 
developed to combat the effects on HIV-1 on proteins and cells pertinent to normal brain 
function.
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  those	  from	  all	  career	  paths	  and	  walks	  of	  life.	  	  Thank	  you	  guys,	  you’re	  all	  too	  awesome	  for	  words,	  honestly.	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1.0	  INTRODUCTION	  Human	  immunodeficiency	  virus	  type	  1	  (HIV)	  infection	  affects	  an	  estimated	  40	  million	  people	  worldwide,	  and	  the	  virus	  is	  associated	  with	  disruption	  of	  the	  central	  nervous	  system	  (CNS)	  in	  roughly	  30%	  of	  individuals	  infected	  with	  the	  virus[1].	  HIV-­‐1	  virus	  enters	  the	  CNS	  from	  the	  peripheral	  circulation	  via	  infected	  macrophages.	  This	  infection	  of	  the	  CNS	  is	  an	  early	  event	  that	  occurs	  during	  the	  acute	  phase	  of	  the	  infection[2].	  This	  results	  in	  neurological	  complications	  in	  a	  significant	  number	  of	  individuals	  with	  HIV-­‐1[3].	  The	  primary	  cells	  that	  are	  infected	  with	  HIV-­‐1	  within	  the	  CNS	  are	  macrophages,	  microglia	  and	  a	  small	  proportion	  of	  astrocytes,	  however	  the	  astrocytes	  do	  not	  support	  productive	  infection	  of	  the	  virus[4].	  	   HIV-­‐1-­‐associated	  Neurocognitive	  Disorders	  (HAND)	  affects	  ~40	  –	  60%	  of	  HIV-­‐1	  patients	  who	  are	  not	  on	  cART	  and	  ~20%-­‐40%	  of	  those	  on	  cART.	  HAND	  occurs	  when	  HIV	  enters	  the	  CNS	  and	  impacts	  the	  integrity	  and	  health	  of	  specific	  cells	  within	  the	  brain.	  This	  impact	  of	  HIV-­‐1	  on	  the	  neuronal	  cell	  lineages	  in	  CNS	  can	  impair	  the	  activity	  of	  cells	  involved	  in	  attention,	  memory,	  language,	  problem	  solving,	  and	  decision-­‐making	  –	  activities	  collectively	  known	  as	  cognition[5].	  	  There	  are	  3	  stages	  of	  HAND:	  Asymptomatic	  neurocognitive	  impairment	  (ANI),	  mild/moderate	  neurocognitive	  disorder	  (MND),	  and	  HIV-­‐associated	  dementia	  (HAD).	  Of	  these	  three,	  HAD	  is	  the	  most	  severe	  but	  MND	  is	  the	  most	  common	  type	  of	  HAND	  among	  HIV-­‐1	  patients[3,	  6-­‐9].	  	  Host	  cellular	  gene	  expression	  as	  a	  response	  to	  viral	  infection	  is	  directly	  correlated	  with	  disease	  patterns.	  Previous	  studies	  in	  our	  laboratory	  have	  shown	  that	  one	  of	  the	  host	  cellular	  factor	  that	  was	  found	  to	  be	  affected	  by	  HIV-­‐1	  infection	  (significantly	  downregulated)	  in	  patients	  with	  high	  viral	  load	  was	  neurogranin	  (NRGN)[10].	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Neurogranin	  (NRGN)	  is	  a	  synaptic	  gene	  that	  spans	  7.3kb	  of	  genomic	  DNA	  and	  contains	  four	  exons	  that	  transcribe	  a	  protein	  of	  78	  amino	  acids,	  which	  translated	  to	  about	  17kDa	  protein	  [11].	  NRGN	  is	  present	  primarily	  in	  neurons	  and	  cells	  of	  neuronal	  lineages	  and	  accumulates	  predominantly	  in	  the	  dendritic	  shafts	  and	  spines	  of	  neurons.	  It	  is	  abundantly	  expressed	  in	  the	  cerebral	  cortex,	  hippocampus,	  basal	  ganglia,	  amygdala,	  and	  the	  hypothalamus[12].	  NRGN	  is	  a	  cellular	  factor	  that	  plays	  a	  role	  in	  the	  calcium-­‐calmodulin	  signaling	  pathway	  and	  has	  been	  suggested	  to	  play	  a	  role	  in	  learning	  and	  memory	  and	  acts	  as	  a	  substrate	  for	  protein	  kinase	  C	  (PKC)	  [13-­‐16].	  Currently,	  detection	  of	  NRGN	  in	  cerebral	  spinal	  fluid	  (CSF)	  is	  used	  as	  a	  biomarker	  for	  Alzheimer’s	  Disease	  (AD)[17].	  NRGN	  is	  involved	  in	  synaptic	  plasticity	  and	  long-­‐term	  potentiation	  (LTP)	  and	  is	  currently	  characterized	  as	  a	  synaptic	  gene[18,	  19].	  LTP	  is	  an	  important	  process	  involved	  in	  learning	  and	  memory,	  which	  are	  key	  parts	  of	  cognition	  that	  are	  affected	  by	  HIV-­‐1	  infection	  in	  the	  brain	  and	  synaptic	  degeneration	  [19,	  20].	  However,	  the	  interaction	  between	  HIV-­‐1	  and	  NRGN	  and	  the	  downstream	  effects	  of	  HIV-­‐1	  infection	  on	  the	  expression	  and	  degradation	  of	  NRGN	  is	  not	  well	  defined.	  The	  work	  performed	  here	  is	  to	  define	  the	  role	  of	  HIV-­‐1	  -­‐	  NRGN	  interaction	  and	  its	  effects	  using	  an	  in	  vitro	  model.	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2.0	  BACKGROUND	  
2.1.	  VIRAL	  GENOME	  ORGANIZATION	  The	  HIV	  viral	  genome	  consists	  of	  structural	  and	  enzymatic	  genes	  (gag,	  pol,	  and	  env),	  two	  regulatory	  elements	  (tat	  and	  rev),	  and	  several	  accessory	  genes	  (vif,	  vpr,	  vpu	  and	  nef)	  that	  are	  flanked	  by	  long	  terminal	  repeats	  (LTRs)[21,	  22].	  The	  5’LTR	  serves	  as	  a	  promoter	  to	  signal	  for	  viral	  gene	  expression.	  The	  signals	  include	  sequences	  that	  allow	  for	  transcription	  initiation,	  termination,	  and	  poly-­‐adenylation,	  and	  elements	  that	  direct	  reverse	  transcription.	  	  
Figure	  1.	  HIV	  gene	  organization.	  
The	  genomic	  organization	  schematic	  in	  Figure	  1	  shows	  reading	  frames	  necessary	  for	  the	  production	  of	  the	  viral	  proteins[23].	  The	  largest	  genes	  –	  gag,	  pol,	  and	  env	  –	  encode	  structural	  proteins	  of	  the	  virus	  particles.	  	  gag	  transcription	  makes	  the	  Gag	  poly-­‐protein,	  which	  is	  cleaved	  to	  produce	  the	  matrix	  (MA),	  the	  capsid	  (CA),	  and	  the	  nucleocapsid	  (NC)	  proteins	  that	  encapsulate	  the	  virion.	  pol	  transcription	  results	  in	  enzymes	  that	  have	  multiple	  functions,	  including	  integrase	  (IN),	  protease	  (PR),	  and	  reverse	  transcriptase	  (RT)	  with	  RNase	  H	  activity[24].	  Transcription	  of	  env	  leads	  to	  the	  formation	  of	  the	  envelope	  protein	  present	  in	  the	  viral	  membrane.	  The	  transcribed	  proteins	  form	  a	  hetero-­‐trimer	  that	  binds	  to	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the	  host	  CD4	  glycoprotein	  and	  the	  chemokine	  co-­‐receptor	  (CXCR4	  or	  CCR5)	  to	  allow	  for	  viral	  entry	  into	  the	  cell.	  A	  gag-­‐pol	  poly-­‐protein	  is	  also	  produced	  in	  low	  levels,	  indicated	  by	  the	  presence	  of	  pol	  enzymes	  in	  the	  virion	  structure.	  	  Tat	  and	  Rev	  are	  required	  for	  viral	  transcription	  and	  protein	  translation.	  After	  viral	  integration,	  low	  levels	  of	  viral	  RNA	  transcripts	  are	  primarily	  produced,	  which	  produces	  low	  levels	  of	  Tat.	  Tat	  enhances	  the	  rate	  and	  efficiency	  of	  viral	  transcription	  via	  binding	  to	  a	  RNA	  hairpin	  structure	  at	  the	  5’	  end	  of	  viral	  transcripts	  –	  the	  trans-­‐activating	  response	  element	  (TAR).	  When	  bound	  to	  TAR,	  Tat	  then	  interacts	  with	  RNA	  Polymerase	  II,	  therefore	  upregulating	  polymerase	  efficiency[25].	  Rev	  controls	  the	  nuclear	  export	  of	  unspliced	  and	  partially	  spliced	  viral	  transcripts,	  regulating	  the	  production	  of	  viral	  genomes	  and	  structural	  proteins.	  Without	  Rev,	  viral	  transcripts	  remain	  in	  the	  nucleus	  and	  are	  fully	  spliced	  –	  only	  producing	  Rev,	  Tat,	  and	  the	  accessory	  protein	  Nef.	  Rev	  works	  by	  binding	  to	  the	  Rev	  response	  element	  (RRE),	  a	  351-­‐nucleotide	  RNA	  sequence	  encoded	  within	  the	  unspliced	  env	  gene[26,	  27].	  When	  Rev	  binds	  to	  the	  RRE,	  it	  exports	  unspliced	  and	  partially-­‐spliced	  viral	  transcripts	  into	  the	  cytosol	  before	  complete	  splicing,	  allowing	  for	  the	  translation	  of	  structural	  proteins	  and	  viral	  RNA	  genome	  for	  virion	  incorporation[28].	  	  The	  accessory	  genes	  of	  HIV-­‐1,	  which	  include	  nef,	  vif,	  vpr,	  and	  vpu	  are	  not	  completely	  necessary	  for	  viral	  infection	  but	  do	  play	  a	  major	  role	  in	  augmentation	  of	  infection	  and	  replication	  efficiency.	  Nef	  aids	  in	  the	  degradation	  of	  CD4	  glycoprotein,	  in	  addition	  to	  interruption	  of	  cellular	  signal	  transductions;	  Vif	  interrupts	  antiviral	  activity	  of	  APOBEC3G,	  a	  host	  restriction	  factor;	  Vpr	  regulates	  nuclear	  import	  and	  is	  present	  in	  the	  pre-­‐integration	  complex;	  and	  Vpu	  aids	  in	  the	  degradation	  of	  CD4	  and	  tetherin	  in	  infected	  cells[29-­‐32].	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2.2.	  HIV-1	  VIRAL	  ENTRY	  AND	  ESTABLISHMENT	  OF	  INFECTION	  The	  human	  immunodeficiency	  virus-­‐1	  (HIV-­‐1)	  belongs	  to	  the	  Lentivirus	  genus	  of	  the	  Retroviridae	  family.	  The	  HIV-­‐1	  virion	  contains	  structural	  proteins,	  two	  single-­‐stranded	  RNA	  molecules,	  and	  several	  enzymatic	  proteins	  necessary	  to	  establish	  infection.	  The	  capsid	  of	  the	  virion	  is	  enveloped	  with	  a	  lipid	  bilayer,	  which	  also	  contains	  the	  viral	  envelope	  proteins.	  HIV-­‐1	  infects	  its	  target	  cells	  through	  the	  use	  of	  gp120,	  the	  surface	  viral	  envelope	  glycoprotein.	  gp120	  interacts	  with	  the	  CD4	  antigen	  present	  on	  target	  cells,	  along	  with	  one	  of	  two	  potential	  chemokine	  co-­‐receptors:	  CCR5	  or	  CXCR4.	  The	  interactions	  between	  host	  CD4	  and	  viral	  gp120	  stabilizes	  the	  virus-­‐host	  binding	  to	  facilitate	  secondary	  interactions	  between	  gp120	  and	  the	  co-­‐receptors.	  These	  interactions	  facilitate	  a	  conformational	  change	  in	  the	  viral	  transmembrane	  protein	  gp41	  that	  allows	  for	  fusion	  to	  the	  membrane	  and	  entry	  of	  the	  capsid	  into	  the	  host	  cell	  [33-­‐36].	  	  Upon	  entry	  of	  the	  capsid	  into	  the	  cytosol	  of	  the	  host,	  the	  preintegration	  complex	  (PIC)	  is	  formed.	  This	  complex	  is	  composed	  of	  accessory	  protein	  viral	  protein	  R	  (Vpr),	  reverse	  transcriptase,	  capsid	  gag	  proteins	  (matrix	  proteins	  and	  p24),	  integrase,	  and	  two	  copies	  of	  the	  single-­‐stranded	  RNA	  viral	  genome[37].	  When	  the	  PIC	  is	  released	  into	  the	  host	  cytosol	  the	  process	  of	  reverse	  transcription	  begins,	  resulting	  in	  a	  double-­‐stranded	  proviral	  DNA	  product	  that	  is	  capable	  of	  integration.	  The	  PIC	  then	  moves	  through	  the	  nuclear	  envelope	  and	  enters	  into	  the	  nucleus	  by	  way	  of	  active	  transport	  through	  the	  nuclear	  pore	  complex.	  When	  the	  PIC	  enters	  the	  nucleus,	  the	  proviral	  DNA	  is	  integrated	  into	  the	  host	  genome,	  allowing	  for	  initiation	  of	  virus	  production	  and	  establishing	  infection[38,	  39].	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2.3.	  AIDS	  EPIDEMIC	  AND	  HAND	  PROGRESSION	  Globally,	  there	  are	  currently	  an	  estimated	  35.3	  million	  individuals	  infected	  with	  HIV	  -­‐1	  and	  millions	  of	  new	  cases	  reported	  yearly[40].	  	  HIV-­‐1	  virus	  primarily	  infects	  two	  target	  cells	  of	  the	  immune	  system	  –	  macrophages	  and	  CD4+	  T	  cells.	  CD4+	  T	  cell	  count	  is	  used	  as	  a	  marker	  for	  HIV-­‐1	  progression[41].	  	  Natural	  HIV	  infection	  is	  characterized	  by	  three	  major	  stages	  –	  acute	  infection	  (Stage	  1),	  clinical	  latency	  (Stage	  2),	  and	  Acquired	  Immune	  Deficiency	  Syndrome	  (AIDS)	  (Stage	  3).	  Presently,	  most	  infected	  individuals	  infected	  with	  HIV-­‐1	  are	  treated	  with	  cART	  and	  therefore	  progression	  to	  AIDS	  is	  minimum[42-­‐44].	  The	  acute	  infection	  stage	  occurs	  2-­‐4	  weeks	  after	  infection	  and	  during	  this	  time,	  the	  virus	  replicates	  and	  as	  the	  viral	  load	  increases,	  the	  CD4+	  T	  cell	  count	  decreases	  until	  the	  viral	  set	  point	  is	  reached.	  At	  the	  viral	  set	  point,	  the	  immune	  system	  responds	  and	  stabilizes	  the	  level	  of	  the	  virus	  and	  increases	  the	  CD4+	  T	  cell	  count	  minimally.	  	  The	  clinical	  latency	  stage,	  based	  on	  the	  infected	  individual’s	  disease	  progression,	  lasts	  from	  8	  –	  20	  years	  and	  is	  the	  stage	  at	  which	  the	  virus	  replicates	  at	  low	  levels	  and	  the	  infected	  individual	  can	  show	  a	  healthy	  CD4+	  T	  cell	  count	  and	  undetectable	  viral	  load	  levels.	  It	  is	  towards	  the	  end	  of	  this	  period	  in	  which	  the	  virus	  begins	  to	  rapidly	  replicate,	  causing	  a	  decrease	  in	  bystander	  CD4+	  T	  cells[45].	  	  When	  the	  CD4+	  T	  cell	  count	  decreases	  below	  200	  cells/mm3,	  the	  infected	  individual	  is	  then	  diagnosed	  with	  AIDS.	  The	  individual	  will	  in	  time	  succumb	  to	  opportunistic	  infections	  that	  a	  healthy	  individual	  would	  normally	  be	  able	  to	  fight	  off[42,	  46].	  Currently,	  there	  is	  no	  cure	  for	  HIV-­‐1,	  but	  there	  are	  treatments	  available	  to	  combat	  viral	  replication	  within	  the	  body	  in	  the	  form	  of	  antiretroviral	  treatment.	  Antiretrovirals	  are	  separated	  into	  six	  different	  classes	  based	  on	  the	  way	  the	  drugs	  interfere	  with	  certain	  stages	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of	  HIV-­‐1	  replication	  within	  the	  body[47].	  The	  first	  class	  of	  these	  drugs	  is	  the	  entry	  inhibitors,	  which	  interfere	  with	  the	  ability	  of	  the	  virus	  to	  bind	  to	  receptors	  on	  the	  outer	  surface	  of	  the	  cell,	  as	  it	  attempts	  to	  enter.	  With	  failed	  receptor	  binding,	  the	  virus	  cannot	  infect	  the	  cell.	  	  The	  second	  group,	  the	  fusion	  inhibitors,	  interferes	  with	  fusion	  of	  the	  virus	  to	  the	  cellular	  membrane,	  which	  keeps	  the	  virus	  from	  entering	  the	  cell.	  Reverse	  transcriptase	  inhibitors	  prevent	  reverse	  transcription	  –	  a	  process	  in	  which	  the	  HIV	  enzyme	  reverse	  transcriptase	  (RT)	  converts	  single-­‐stranded	  HIV	  RNA	  into	  double-­‐stranded	  HIV	  DNA.	  Integrase	  inhibitors	  block	  the	  viral	  enzyme	  integrase,	  which	  the	  virus	  needs	  to	  integrate	  its	  genetic	  material	  into	  the	  DNA	  of	  the	  infected	  cell.	  Next,	  protease	  inhibitors	  interfere	  with	  the	  HIV-­‐1	  enzyme	  protease,	  which	  processes	  HIV-­‐1	  precursors	  and	  polyproteins	  into	  smaller	  individual	  proteins.	  With	  the	  protease	  inactive,	  new	  virus	  particles	  cannot	  be	  assembled.	  The	  last	  group	  is	  the	  multi-­‐class	  combination	  products,	  which	  combine	  HIV-­‐1	  drugs	  from	  two	  or	  more	  classes	  into	  a	  single	  product[47].	  	  HIV-­‐1	  has	  the	  ability	  to	  affect	  the	  brain	  by	  way	  of	  passing	  the	  Blood-­‐Brain	  Barrier	  (BBB)[48].	  Early	  in	  the	  course	  of	  HIV-­‐1	  disease	  progression,	  infected	  macrophages	  cross	  the	  BBB[49]	  and	  establish	  infection	  within	  the	  brain.	  Microglia,	  macrophages	  and	  astrocytes	  are	  major	  HIV-­‐1	  targets	  in	  the	  brain,	  whereas	  HIV-­‐1	  infected	  neurons	  have	  been	  rarely	  observed,	  suggesting	  that	  indirect	  mechanisms	  may	  account	  for	  the	  severe	  neuronal	  damage	  observed	  in	  patients	  with	  HAND[50-­‐52].	  	  
Soluble	  viral	  proteins,	  such	  as	  gp120,	  Vpr,	  and	  Tat,	  are	  also	  known	  to	  be	  potent	  neurotoxins,	  which	  contribute	  to	  neuronal	  death	  and	  the	  onset	  of	  HAND	  in	  patients	  [53].	  The	  neurocognitive	  impairment	  caused	  by	  HIV-­‐1	  infection	  is	  HIV-­‐associated	  Neurocognitive	  Disorders	  (HAND).	  HAND	  occurs	  when	  the	  HIV-­‐1	  virus	  enters	  the	  central	  nervous	  system	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(CNS)	  and	  compromises	  the	  health	  of	  the	  neurons[5].	  	  	  Virus	  particularly	  impairs	  the	  brain	  cells	  involved	  in	  attention,	  language,	  memory,	  decision	  making,	  and	  problem	  solving	  –	  activities	  collectively	  known	  as	  cognition[48].	  There	  are	  many	  symptoms	  of	  HAND,	  such	  as	  forgetfulness,	  headaches,	  gradual	  weakening	  and	  loss	  of	  feeling	  in	  extremities,	  and	  confusion[5].	  
HAND	  has	  three	  stages	  in	  which	  an	  infected	  individual	  can	  progress	  through.	  The	  first	  of	  which	  is	  the	  Asymptomatic	  Neurocognitive	  Impairment	  (ANI),	  in	  which	  the	  infected	  individual	  shows	  cognitive	  impairment,	  but	  the	  impairment	  does	  not	  hinder	  everyday	  function.	  The	  second	  stage	  is	  Mild	  Neurocognitive	  Disorder	  (MND),	  where	  the	  affected	  individual	  shows	  impairment	  and	  there	  is	  a	  mild	  interference	  in	  everyday	  function.	  The	  third	  and	  last	  stage	  of	  HAND	  is	  HIV-­‐1	  associated	  Dementia	  (HAD).	  Individuals	  that	  have	  progressed	  to	  HAD	  present	  severe	  impairment	  in	  information	  processing	  and	  new	  information	  retention	  that	  greatly	  impact	  the	  daily	  life	  of	  the	  individual[5,	  54].	  ANI	  and	  NMD	  affect	  20	  –	  40%	  of	  HIV-­‐1	  infected	  individuals	  where	  HAD	  has	  become	  less	  common	  with	  the	  advent	  of	  Highly	  active	  antiretroviral	  therapy	  in	  1996	  (Figure	  2)[54,	  55].	  	  	  
The	  prevalence	  of	  HAND	  is	  significant	  in	  patients	  with	  well-­‐controlled	  HIV-­‐1	  and	  this	  prevalence	  has	  been	  associated	  with	  decreased	  quality	  of	  life,	  increased	  mortality,	  and	  poor	  adherence	  to	  treatment.	  This	  poor	  adherence	  to	  treatment	  causes	  concern	  as	  it	  could	  lead	  to	  drug	  resistance[56].	  	  The	  cause	  of	  HAND	  as	  well	  as	  its	  prevalence	  despite	  the	  effectiveness	  of	  HAART	  is	  currently	  unknown,	  but	  there	  are	  many	  theories	  on	  the	  contributors	  to	  the	  development	  of	  HAND.	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Figure	  2.	  Prevalence	  of	  HAND	  comparing	  the	  preV HAART	  era	  to	  the	  current	  era	  
of	  widespread	  HAART	  usage.	  	  
Reprinted	  with	  permission	  from	  Wiley	  Publishers	  Ltd:	  ANNALS	  OF	  NEUROLOGY,	  Human	  immunodeficiency	  virus-associated	  neurocognitive	  disorders:	  Mind	  the	  gap,	  2010	  [55].	  
2.4.	  POTENTIAL	  CONTRIBUTORS	  TO	  HAND	  
           Though	  the	  advent	  of	  HAND	  has	  decreased	  the	  incidence	  of	  HAD,	  ANI	  and	  MND	  still	  continue	  to	  affect	  20	  –	  40%	  of	  HIV-­‐1	  infected	  individuals	  on	  HAART[5].	  Although	  the	  incidence	  of	  HAD	  has	  decreased,	  its	  prevalence	  is	  actually	  increasing,	  due	  to	  the	  longer	  life	  expectancy	  for	  individuals	  with	  HIV-­‐1	  and	  to	  patient	  resistance	  to	  HAART	  drugs[57].	  While	  neuronal	  cell	  damage	  and	  death	  are	  associated	  with	  the	  development	  and	  progression	  of	  HAND	  symptoms,	  HIV	  does	  not	  directly	  infect	  neurons	  [57].	  The	  cause	  of	  neuronal	  cell	  death	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and	  dysfunction	  and	  HAND	  is	  currently	  not	  fully	  defined,	  both	  direct	  and	  indirect	  effects	  are	  reported.	  Some	  of	  these	  explanations	  include	  that	  there	  is	  accelerated	  brain	  aging	  due	  to	  increased	  β-­‐amyloid	  and	  tau	  depositions	  facilitated	  by	  HIV-­‐1	  infection,	  toxicity	  of	  HAART	  on	  the	  CNS,	  inadequate/partial	  entry	  of	  HAART	  in	  the	  CNS,	  and	  depletion	  of	  neuronal	  cells,	  and	  the	  HIV-­‐1	  envelope	  protein,	  gp120,	  elevates	  intracellular	  free	  calcium,	  leading	  to	  neuronal	  damage[56,	  58-­‐61].	  	  	  
Numerous	  studies	  have	  provided	  a	  strong	  role	  for	  inflammation	  in	  triggering	  events	  leading	  to	  neurodegeneration	  in	  HIV	  infection.	  The	  association	  between	  the	  increase	  of	  activated	  macrophages/microglia	  in	  the	  CNS,	  neuronal	  damage,	  and	  cognitive	  dysfunction	  suggests	  that	  neuroinflammation	  resulting	  from	  systemic	  immune	  activation	  and/or	  inflammation	  triggers	  the	  neurodegeneration	  observed	  in	  HAND[62].	  	  
Neurons	  are	  vulnerable	  to	  direct	  damage	  by	  several	  viral	  proteins	  –	  particularly	  Tat	  and	  gp120.	  This	  is	  mainly	  mediated	  through	  the	  presence	  of	  the	  neuronal	  cell	  surface	  receptors,	  particularly	  the	  N-­‐methyl-­‐D-­‐Aspartate	  receptors	  (NMDAR),	  dopamine	  transporter,	  and	  the	  chemokine	  receptors	  CCR5	  and	  CXCR4.	  Glutamate	  is	  the	  most	  abundant	  neurotransmitter	  in	  the	  brain,	  and	  is	  responsible	  for	  spreading	  excitatory	  signal	  transmission	  by	  binding	  to	  NMDAR	  and	  opening	  cation-­‐specific	  channels	  in	  the	  cell	  membrane,	  allowing	  the	  influx	  of	  sodium	  and	  calcium	  ions	  and	  the	  efflux	  of	  potassium	  ions[63].	  The	  two	  major	  viral	  proteins	  that	  interact	  with	  the	  above	  receptors	  to	  cause	  neuronal	  injury	  are	  gp120	  and	  Tat.	  HIV-­‐1	  gp120	  directly	  binds	  NMDAR	  on	  human	  embryonic	  neurons	  and	  can	  cause	  a	  lethal	  influx	  of	  calcium	  ions	  (Figure	  3)[64].	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Figure	  3.	  Model	  of	  HIV-­‐1	  related	  brain	  damage.	  Reprinted	  with	  permission	  from	  Macmillan	  Publishers	  Ltd:	  NATURE,	  Pathways	  to	  neuronal	  injury	  and	  apoptosis	  in	  HIV-­‐associated	  dementia,	  2001[65].	  
2.5.	  NEUROGRANIN	  Neurogranin	   (NRGN)	   is	   a	   synaptic	   gene	   that	   spans	   7.3kb	   of	   genomic	   DNA	   and	  contains	   four	   exons	   that	   transcribe	   a	   protein	   of	   78	   amino	   acids,	   which	   translated	   to	  ~17kDa[12,	   13].	   NRGN	   is	   present	   primarily	   in	   neurons	   and	   cells	   of	   neuronal	   lineages	   and	  accumulates	  predominantly	  in	  the	  dendritic	  shafts	  and	  spines	  of	  neurons	  and	  is	  abundantly	  expressed	   in	   the	   cerebral	   cortex,	   hippocampus,	   basal	   ganglia,	   amygdala,	   and	   the	  hypothalamus[66].	   NRGN	   is	   a	  member	   of	   the	   calpacitin	   protein	   family,	   a	   class	   of	   proteins	  whose	   role	   is	   to	   control	   the	   level	   and	   activation	   state	   of	   calmodulin[67].	   The	   calpacitin	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proteins	   are	   small,	   abundantly	   expressed	   proteins	   that	   bind	   to	   the	   Ca2+-­‐free	   form	   of	  calmodulin	   (CaM)	   with	   an	   affinity	   equal	   to	   or	   greater	   than	   that	   of	   the	   Ca2+-­‐containing	  form[12,	  13,	  68,	  69].	   The	  most	   characterized	   proteins	   of	   this	   class	   are	   Purkinje	   cell	   protein	   4	  (PEP-­‐19),	  neuromodulin	  (Nm),	  and	  neurogranin	  (NRGN)[69].	  NRGN	  is	  a	  cellular	  factor	  that	  plays	  a	  role	  in	  the	  calcium-­‐calmodulin	  signaling	  pathway	  and	  has	  been	  suggested	  to	  play	  a	  role	  in	  learning	  and	  memory	  and	  acts	  as	  a	  substrate	  for	  protein	  kinase	  C	  (PKC),	  specifically	  the	  PKC	  isoform	  γ	  (PKCγ)[13,	  14,	  70,	  71].	  	  NRGN	   has	   been	   shown	   to	   be	   involved	   in	   synaptic	   plasticity	   and	   long-­‐term	  potentiation	  (LTP)	  and	   is	  currently	  characterized	  as	  a	  synaptic	  gene	  [19].	   In	   the	  process	  of	  LTP,	  NRGN	  is	  phosphorylated	  by	  PKCγ[72-­‐74].	  Once,	  phosphorylated,	  NRGN	  dissociates	  from	  Ca2+	  and	   localizes	   to	   the	   nucleus	  where	   its	   function	   is	   not	   yet	   understood[75,	  76].	   LTP	   is	   a	  very	  important	  process	  involved	  in	  learning	  and	  memory,	  which	  are	  key	  parts	  of	  cognition	  that	  are	  affected	  by	  HIV-­‐1	  infection	  in	  the	  brain	  and	  synaptic	  degeneration	  [19,	  20].	  LTP	  can	  be	  produced	  by	  activating	  N-­‐methyl-­‐D-­‐aspartate	  (NMDA)-­‐type	  glutamate	  receptors,	  by	  the	  synchronized	  activity	  of	  pre-­‐	  and	  postsynaptic	  neurons[18].	  Degradation	   of	   NRGN	   has	   been	   linked	   to	   neurocognitive	   disorders,	   such	   as	  Alzheimer’s	   Disease[77-­‐81].	   Currently,	   detection	   of	   NRGN	   in	   cerebral	   spinal	   fluid	   (CSF)	   is	  used	  as	  a	  biomarker	  for	  Alzheimer’s	  Disease	  (AD)	  as	  degraded	  NRGN	  from	  the	  neurons	  are	  released	  into	  the	  CSF[17,	  82].	  	  Individuals	  infected	  with	  HIV-­‐1	  and	  have	  a	  high	  viral	  load	  show	  a	  downregulation	  of	  NRGN[10].	  It	  is	  currently	  unclear	  if	  these	  individuals	  could	  progress	  to	  HAND,	  and	  whether	  degradation	  of	  NRGN	  could	  be	  a	  potential	  contributor	  to	  this	  disorder.	  	  
     It	  would	  be	  ideal	  to	  study	  the	  interactions	  between	  HIVA 1	  infection	  in	  the	  brain	  and	  its	  effects	  on	  the	  production/degradation	  of	  NRGN	  and	  how,	  if	  at	  all,	  it	  contributes	  to	  HAND.	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Investigating	  how	  NRGN	   is	  degraded	  and/or	  downregulated	   in	   infected	   individuals	  could	  gain	  insight	  in	  possibly	  predicting	  the	  development	  of	  HAND	  in	  infected	  individuals	  as	  well	  as	  developing	  therapies	  to	  curb	  the	  degradation	  or	  fully	  combat	  it.	  
2.6.	  microRNAs	  (miRNAs)	  	  
              MicroRNAs	  (miRNAs)	  are	  a	  class	  of	  recently	  discovered	  22–24	  nucleotide	  RNA	  molecules	  that	  bind	  in	  an	  imperfect	  complementarity	  to	  their	  target	  messenger	  RNAs	  (mRNAs)	  within	  the	  3′A UTR	  (untranslated	  region).	  miRNAs	  are	  conserved	  across	  species,	  expressed	  across	  cell	  types,	  and	  active	  against	  a	  large	  proportion	  of	  the	  transcriptome[83].	  This	  binding	  to	  target	  mRNAs	  can	  prevent	  them	  from	  being	  translated	  into	  proteins[84,	  85].	  Since	  their	  discovery,	  much	  progress	  has	  been	  made	  in	  understanding	  their	  biogenesis	  and	  target	  site	  recognition	  within	  their	  target	  mRNAs[86,	  87].	  Currently,	  it	  is	  still	  unclear	  how	  miRNAs	  repress	  gene	  expression	  but	  what	  available	  data	  suggest	  that	  there	  are	  interrelated	  processes	  involved	  in	  miRNAA mediated	  repression	  of	  gene	  expression.	  It	  has	  been	  shown	  that	  most	  miRNAA repressed	  mRNAs	  are	  subject	  to	  deadenylation	  and	  mRNA	  destabilization[87,	  88].	  These	  events	  appear	  to	  be	  in	  addition	  to	  translational	  repression,	  since	  mRNAs	  that	  do	  not	  have	  a	  poly(A)	  tail	  (they	  are	  substituted	  with	  a	  histone	  stem	  loop)	  are	  still	  subject	  to	  miRNA-­‐mediated	  translational	  repression	  without	  mRNA	  destabilization[88].	  Recently	  it	  has	  been	  shown	  that	  translational	  repression	  occurs	  prior	  to	  deadenylation	  and	  destabilization[89].	  	  
HIV-­‐1	  infection	  mRNA	  analysis	  has	  show	  that	  miRNA	  binding	  to	  the	  3’UTR	  regions	  of	  mRNAs	  can	  either	  upregulate	  or	  downregulate	  particular	  protein	  production[10].	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Previous	  studies	  in	  our	  lab	  show	  that	  there	  is	  a	  potential	  interaction	  between	  mir-­‐564	  and	  the	  3’UTR	  of	  NRGN	  that	  downregulate	  the	  production	  of	  the	  protein[10].	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3.0	  THESIS	  AIMS	  
	   The	  following	  are	  the	  specific	  aims	  designed	  to	  investigate	  how	  HIV-­‐1	  infection	  impacts	  the	  levels	  of	  NRGN	  present	  in	  neurons,	  possibly	  becoming	  a	  contributing	  factor	  to	  HAND.	  	  Aim	  1:	  Characterization	  of	  endogenous	  and	  over-­‐expressed	  NRGN	  in	  neuronal	  cell	  lines.	  A. Determine	  the	  endogenous	  expression	  in	  neuronal	  cell	  lines	  by	  performing	  immunoblot	  against	  NRGN	  and	  qRT-­‐PCR	  to	  determine	  mRNA	  transcript	  levels.	  B. Clone	  and	  express	  NRGN-­‐with	  tag	  (FLAG)	  to	  determine	  localization	  of	  the	  protein	  within	  neuronal	  cell	  lines.	  C. Localization	  of	  endogenous	  NRGN	  in	  neuronal	  cells	  using	  immunofluorescence	  staining	  of	  NRGN.	  
Aim	  2:	  Examine	  the	  effect	  of	  HIV-­‐1	  infection/exposure	  on	  NRGN	  expression	  in	  neuronal	  cell	  lines	  A. Determine	  whether	  neuronal	  cell	  lines	  express	  HIV-­‐1	  receptors	  and	  co-­‐receptors	  by	  flow	  cytometry.	  B. Infection	  and	  exposure	  of	  neuronal	  cell	  lines	  with	  chimeric	  reporter	  viruses	  previously	  constructed	  in	  our	  lab.	  i. NL-­‐YU2-­‐env	  (CCR5	  receptor	  utilizing	  virus	  isolated	  from	  the	  brain)ii. NL43	  (CXCR4	  co-­‐receptor	  utilizing	  virus)
Aim	  3:	  Determine	  if	  NRGN	  is	  degraded	  by	  HIV-­‐1	  infection	  A. Using	  a	  3’UTR-­‐NRGN-­‐Luc	  transfected	  into	  HeLa	  cells	  to	  determine	  if	  degradation	  occurs	  at	  the	  3’UTR	  of	  NRGN.	  
16	  
4.0	  MATERIALS	  AND	  METHODS	  
4.1.	  CULTURING	  OF	  NEURONAL	  CELL	  LINES	  
           The	  A172	  cell	  line	  is	  a	  brain	  glioblastoma	  cell	  line.	  This	  astrocytic	  tumor	  cell	  line	  that	  is	  known	  to	  hypoexpress	  NRGN[90].	  	  NA TTERA	  2/D1	  (NT2)	  cell	  line	  is	  a	  clonally	  derived	  pluripotent	  human	  embryonal	  carcinoma	  cell	  line	  isolated	  from	  the	  lung	  of	  patient	  and	  cultured	  using	  retinoic	  acid	  to	  a	  neuronally	  committed	  human	  teratocarcinoma	  cell	  line.	  [91].	  The	  SH-­‐SY5Y	  cell	  line	  was	  derived	  from	  original	  cell	  line,	  SK-­‐N-­‐SH	  which	  was	  isolated	  from	  a	  four	  year-­‐old	  female	  with	  neuroblastoma	  [92].	  Neuronal	  cell	  lines	  A172,	  SH-­‐SY5Y	  and	  NT2	  cultures	  were	  maintained	  as	  confluent	  monolayers	  at	  37°C	  with	  5%	  CO2	  and	  90%	  humidity	  in	  D-­‐10	  media	  (DMEM	  with	  10%	  fetal	  calf	  serum,	  20mM	  HEPES,	  2mM	  L-­‐glutamine).	  	  
4.2.	  CONSTRUCTION	  OF	  NRGN	  WITH	  FLAG	  TAG	  
            Forward	  and	  reverse	  primers	  were	  determined	  to	  PCR	  amplify	  NRGN	  cDNA	  and	  obtained	  from	  IDT	  (Coralville,	  Iowa).	  The	  reverse	  primer	  was	  designed	  to	  include	  sequence	  for	  the	  FLAG	  tag.	  pcDNA™3.1⁄V5A His	  TOPO®	  TA	  Expression	  Kit	  (Life	  Technologies)	  was	  used	  to	  ligate	  the	  DNA	  into	  pcDNA3.1⁄V5A HisA TOPO®	  vector.	  The	  ligation	  was	  transformed	  into	  TOP10	  competent	  cells	  (Life	  Technologies)	  and	  plated	  on	  100µg/ml	  ampicillin	  plates.	  	  
4.3.	  CONFIRMATION	  OF	  NRGN-­‐FLAG/NRGN	  CLONES	  
	             Clones	  were	  confirmed	  by	  performing	  boiling	  lysis	  prep	  to	  attain	  the	  DNA	  of	  transformed	  TOP	  10	  cells.	  The	  DNA	  was	  collected	  and	  a	  restriction	  digest	  was	  performed	  using	  EcoRI	  and	  XhoI	  for	  the	  pNRGNA FLAG	  tagged	  clone	  and	  BamHI	  for	  the	  pNRGN	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clone. DNA used for restriction	  digest	  was	  yielded	  using	  a	  boiling	  prep	  method.	  Mini	  preps	  (Qiagen)	  were	  done	  on	  the	  clones	  that	  showed	  a	  band	  size	  of	  ~330bp	  and	  the	  prepped	  DNA	  was	  sent	  for	  sequencing.	  The	  clones	  that	  had	  the	  proper	  DNA	  sequence	  were	  then	  grown	  in	  E.coli	  culture	  and	  the	  DNA	  harvested	  via	  maxiprep	  (Qiagen)	  and	  stored.	  	  
4.4.	  WESTERN	  BLOT	  ASSESSMENT	  FOR	  NEUROGRANIN	  (NRGN)	  
             Whole	  cell	  lysates	  were	  prepared	  using	  RIPA	  buffer	  (containing	  50mM	  Tris	  (pH	  7.5)),	  150mM	  NaCl,	  1%	  Triton	  XA 100,	  1mM	  sodium	  orthovanadate,	  10mM	  sodium	  fluoride,	  1mM	  phenylmethylA sulfonylfluoride,	  0.05%	  deoxycholate,	  10%	  SDS,	  0.07	  trypsin	  and	  protease	  inhibitors	  1µg/ml)	  and	  70	  µg	  equivalents	  of	  protein	  were	  separated	  by	  12%	  SDS–PAGE,	  transferred	  to	  polyvinylidene	  difluoride	  (PVDF)	  (BioA Rad).	  The	  PVDF	  membrane	  was	  blocked	  in	  0.5%	  milk	  in	  PBSA T	  for	  2	  hours	  and	  probed	  with	  antiA NRGN	  antibody	  (1:750,	  Santa	  Cruz)	  for	  4°C	  overnight,	  and	  then	  washed	  with	  PBS	  and	  0.1%	  Tween20	  and	  incubated	  with	  goat	  antirabbit	  IgG	  conjugated	  to	  horseradish	  peroxidase	  (1:3000	  Caltag)	  for	  1hr	  at	  room	  temperature.	  	  The	  membrane	  was	  developed	  using	  an	  ECL	  enhanced	  chemiluminescence	  kit	  (Advansta).	  	  
4.5.	  WESTERN	  BLOT	  ASSESSMENT	  FOR	  P24	  
            Whole	  cell	  lysates	  were	  prepared	  using	  RIPA	  buffer	  (containing	  50mM	  Tris	  (pH	  7.5),	  150mM	  NaCl,	  1%	  Triton	  XA 100,	  1mM	  sodium	  orthovanadate,	  10mM	  sodium	  fluoride,	  1mM	  phenylmethylA sulfonylfluoride,	  0.05%	  deoxycholate,	  10%	  SDS,	  0.07	  trypsin	  and	  protease	  inhibitors	  1µg	  /ml)	  and	  70	  µg	  equivalents	  of	  protein	  were	  separated	  by	  12%	  SDS–PAGE,	  transferred	  to	  polyvinylidene	  difluoride	  (PVDF)	  (BioA Rad).	  The	  membrane	  was	  blocked	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membrane was blocked overnight	  in	  0.5%	  milk	  in	  PBSA T	  for	  12	  hours.	  The	  blocking	  buffer	  was	  poured	  off	  and	  the	  primary	  antibody	  (gagA p24	  antibody)	  was	  added	  at	  a	  concentration	  of	  1:500	  and	  incubated	  for	  2	  hours.	  The	  antibody	  was	  discarded	  and	  the	  membrane	  and	  then	  washed	  with	  PBS	  and	  0.1%	  Tween20	  and	  incubated	  with	  rabbit	  antimouse	  IgG	  conjugated	  to	  horseradish	  peroxidase	  (1:3000	  Caltag)	  for	  2hr	  at	  room	  temperature.	  The	  membrane	  was	  developed	  using	  an	  ECL	  enhanced	  chemiluminescence	  kit	  (Advansta).	  
4.6.	  TRANSFECTION	  OF	  NRGNV FLAG/NRGN	  PLASMID	  INTO	  293T	  AND	  TZM	  CELLS.	  
293T	  cells	  and	  TZM	  cells	  were	  seeded	  in	  10cm2	  plates	  and	  allowed	  to	  reach	  85	  –	  90%	  confluence.	  	  The	  cells	  were	  transfected	  with	  FRTA NRGN	  and	  FRA NRGN	  using	  Polyjet	  transfection	  reagent	  (SignaGen).	  After	  12	  –	  18	  hours,	  transfection	  reagent	  was	  removed	  and	  replaced	  with	  complete	  medium	  and	  incubated	  for	  an	  additional	  30	  hours.	  	  
4.7.	  RNA	  ISOLATION	  
             TZM,	  NT2,	  A172,	  SHA SY5Y,	  HeLaA T4	  and	  HeLa	  153	  cells	  were	  used	  for	  RNA	  isolation	  using	  the	  MirVana	  kit	  (Applied	  Biosystems),	  according	  to	  the	  manufacturer’s	  protocol.	  Briefly,	  5	  million	  cells	  were	  lysed	  with	  200μl	  of	  lysis	  buffer.	  Next,	  RNA	  homogenate	  at	  a	  volume	  equaling	  1/10	  of	  lysis	  buffer	  was	  added	  to	  the	  cells,	  and	  the	  cells	  were	  incubated	  on	  ice	  for	  10	  minutes.	  This	  was	  followed	  by	  an	  addition	  of	  acid	  phenol	  chloroform	  at	  a	  volume	  equal	  to	  that	  of	  the	  lysis	  buffer.	  The	  samples	  were	  then	  thoroughly	  vortexed	  for	  30	  seconds	  and	  centrifuged	  for	  five	  minutes	  at	  room	  temperature	  at	  12,000	  rpm.	  The	  aqueous	  phase	  was	  then	  removed.	  Next,	  100%	  ethanol	  was	  added.	  Using	  a	  filter	  cartridge,	  the	  samples	  were	  spun	  and	  washed	  three	  times	  with	  wash	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solutions. Finally, the samples were eluted with 90μl	  of	  preA heated	  elution	  solution.	  RNA	  concentration	  was	  determined	  with	  NanoDrop2000	  spectrophotometer,	  and	  the	  samples	  were	  stored	  at	  A 80°C.	  
4.8.	  GENERATION	  OF	  cDNA	  
            cDNA	  was	  generated	  from	  100ng	  of	  RNA	  using	  the	  High	  Capacity	  cDNA	  Reverse	  Transcription	  Kit	  (Applied	  Biosystems),	  according	  to	  Table	  1.	  The	  PCR	  was	  run	  at	  25°C	  for	  10	  minutes,	  37°C	  for	  120	  minutes,	  85°C	  for	  5	  minutes,	  and	  held	  indefinitely	  at	  4°C.	  The	  cDNA	  was	  then	  either	  kept	  at	  -­‐20°C	  or	  immediately	  used	  for	  qRT	  PCR.	  The	  qRT	  PCR	  was	  run	  in	  20μl	  triplicates	  (according	  to	  Table	  2),	  using	  the	  ABI	  Prism	  7000	  Sequence	  detection	  system,	  set	  at	  50°C	  for	  2	  minutes,	  95°C	  for	  10	  minutes,	  and	  40	  cycles	  of	  95°C	  for	  15	  sec	  and	  60°C	  for	  1	  minute.	  Relative	  expression	  (ddCT)	  was	  calculated	  after	  normalization	  to	  RPLPO.	  
Table	  1.	  Reverse	  transcription	  reagents	  for	  mRNA	  validations	  
Table	  2.	  Real	  Time	  PCR	  reagents	  for	  mRNA	  validations	  
Reagents	   Volume	  (μl)	  cDNA	   20	  Taqman	  Gene	  Expression	  Master	  Mix	   35	  mRNA	  assay	   3.5	  Nuclease-­‐free	  water	   11.5	  
Reagents	   Volume	  (μl)	  RNA	   10	  10X	  RT	  buffer	   2	  25x	  dNTP	   0.8	  Random	  Primer	   2	  Multiscribe	  Reverse	  Transcriptase	   1	  Nuclease-­‐free	  water	   4.2	  Total	   20	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4.9.	  IMMUNOFLUORESCENCE	  STAINING	  	  
          In	  a	  6A well	  plate	  with	  coverslips	  in	  each	  well,	  500,000	  neuronal	  cells	  were	  seeded	  and	  allowed	  to	  adhere	  and	  reach	  a	  confluence	  level	  of	  60	  –	  75%.	  The	  cells	  were	  then	  washed	  with	  PBS	  once	  and	  4%	  paraformaldehyde	  was	  added	  to	  the	  cells	  and	  incubated	  for	  15	  minutes	  at	  room	  temperature.	  The	  cells	  were	  then	  washed	  with	  PBS	  three	  times	  and	  0.5%	  Triton	  XA 100	  (with	  PBS)	  was	  added	  and	  incubated	  at	  room	  temperature	  for	  15	  minutes.	  The	  cells	  were	  then	  washed	  three	  times	  with	  PBS.	  After	  washing,	  the	  cells	  were	  blocked	  with	  2%	  BSA	  in	  PBS	  and	  incubated	  for	  1	  hour	  at	  room	  temperature.	  Next,	  the	  primary	  antibody	  (NRGN	  or	  FLAG)	  was	  added	  at	  a	  dilution	  of	  1:250	  with	  2.0%	  BSA	  for	  1	  hour.	  The	  cells	  were	  then	  washed	  three	  times	  with	  PBS.	  After	  washing,	  the	  secondary	  antibody	  (Alexa	  Fluor	  488)	  was	  added	  to	  the	  cells	  at	  a	  dilution	  of	  1:500.	  The	  cells	  were	  then	  covered	  with	  foil	  and	  kept	  in	  the	  dark	  to	  incubate	  for	  1	  hour.	  After	  incubation,	  the	  cells	  were	  washed	  five	  times	  with	  PBS	  and	  DAPI	  was	  added	  (~70uL)	  and	  kept	  on	  for	  ~30	  seconds.	  The	  cells	  were	  then	  washed	  three	  times	  with	  PBS	  and	  mounted	  onto	  a	  slide	  using	  Gelvitol	  then	  were	  viewed	  using	  a	  fluorescent	  microscope.	  	  
4.10.	  FLOW	  CYTOMETRY	  TO	  DETERMINE	  THE	  EXPRESSION	  OF	  CD4+/CCR5+/CXCR4+	  
RECEPTORS	  IN	  NEURONAL	  CELLS	  	  
            Neuronal	  cells	  were	  trypsinized	  and	  100,000	  cells	  were	  counted	  then	  resuspended	  in	  1.0mL	  FACS	  buffer	  (10%	  FBS	  in	  PBS)	  and	  kept	  on	  ice	  for	  10	  minutes.	  After	  the	  incubation	  on	  ice,	  the	  cells	  were	  spun	  at	  2000rpm	  for	  5	  minutes	  and	  resuspended	  in	  50ul	  of	  FACS	  buffer.	  5uL	  of	  primary	  antibody	  (CD4,	  CCR5,	  or	  CXCR4)	  was	  added	  and	  the	  cells	  were	  kept	  in	  ice	  for	  45	  –	  60	  minutes.	  After	  this	  incubation	  step,	  the	  cells	  were	  washed	  with	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PBS 3 times	  (add	  1mL	  of	  PBS,	  spin	  for	  5	  minutes	  at	  2000rpm)	  and	  then	  resuspended	  in	  500uL	  of	  FACS	  buffer.	  Once	  in	  the	  500uL	  of	  FACS	  buffer,	  the	  cells	  were	  ready	  to	  be	  loaded	  on	  to	  the	  LSRFortessaTM	  	  Cell	  Analyzer	  (BD	  Biosciences).	  Flow	  cytometric	  analysis	  was	  conducted	  using	  FACSDiva®	  software	  (BD	  Biosciences).	  
4.11.	  CHIMERIC	  REPORTER	  VIRUSES	  
           Two	  reporter	  viruses	  used	  were	  generated	  in	  the	  laboratory	  using	  the	  primary	  NL43A EGFP	  vector.	  The	  NL(YUA 2)A EGFP,	  virus	  which	  utilizes	  the	  R5A tropic	  YUA2	  envelope	  region	  and	  the	  NL4A 3A EGFPA IRES	  X4A tropic	  virus	  were	  both	  generated	  by	  Jessica	  K.	  Sparks	  and	  Narasimhan	  Venkatachari,	  respectively.	  	  
4.12.	  TRANSFECTION	  OF	  HIV-­‐1	  CHIMERIC	  PLASMID	  TO	  MAKE	  VIRUS	  
COMPLEMENTED	  WITH	  VSV	  
             In	  a	  10cm2	  plates,	  2x106	  293T	  cells	  were	  seeded	  and	  allowed	  to	  adhere	  for	  24	  hours.	  Once	  the	  cells	  reach	  80	  –	  90%	  confluency,	  cells	  were	  coA transfected	  with	  3µg	  of	  either	  NL43A WT	  or	  NLA YU2	  HIV	  chimeric	  viral	  plasmid	  and	  1µg	  of	  VSVA GAG	  plasmid	  using	  Polyjet	  transfection	  reagent	  (SignaGen).	  The	  transfection	  solution	  was	  left	  on	  the	  cells	  for	  12	  –	  18	  hours	  and	  then	  replaced	  with	  7mL	  DA 10	  media	  for	  48	  hours.	  After	  the	  48	  hours	  (~72	  hours	  postA transfection)	  viral	  particles	  A 	  was	  collected	  and	  used	  for	  infection	  experiments.	  
4.13.	  TZM	  ASSAY	  TO	  DETERMINE	  INFECTIVITY	  OF	  HIVV 1	  CHIMERIC	  VIRUSES	  
            In	  a	  96A well	  plate,	  30,000	  TZMA bl	  cells	  were	  seeded	  per	  well	  in	  a	  total	  volume	  of	  100uL	  and	  incubated	  overnight	  to	  allow	  for	  cell	  adherence.	  Once	  the	  cells	  were	  adherent	  to	  the	  surface	  of the wells, the HIVA 1 chimeric virus was added to the cells in 1:10 serial
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dilutions	  (1:10;	  1:100;	  1:1000)	  in	  a	  total	  volume	  of	  100uL	  in	  triplicate.	  After	  adding	  the	  virus,	  the	  cells	  were	  incubated	  for	  36	  –	  40	  hours.	  Post	  incubation,	  the	  virus	  media	  was	  removed	  from	  the	  cells	  and	  the	  cells	  were	  fixed	  using	  0.5%	  gluteraldehyde.	  Once	  fixed,	  the	  cells	  were	  washed	  twice	  with	  PBS	  and	  100ul	  of	  XA Gal	  substrate	  (Table	  3)	  was	  added	  to	  the	  cells	  and	  incubated	  at	  37°C	  for	  2	  –	  3	  hours.	  In	  order	  to	  stop	  the	  staining	  reaction,	  after	  2A 3	  hours	  incubation,	  the	  cells	  were	  washed	  with	  PBS	  once	  and	  50uL	  of	  PBS	  was	  added	  to	  keep	  the	  cells	  for	  counting.	  	  Table	  3.	  XV Gal	  Staining	  Substrate	  for	  TZM	  Assay	  PBS	   11.10mL	  X-­‐Gal	  (40mg/mL)	   240uL	  0.5M	  MgCl2	   24uL	  K	  Ferrous	  CN	   300uL	  K	  Ferric	  CN	   300uL	  
To	  determine	  the	  number	  of	  infectious	  particles	  (IP)	  per	  mL	  of	  virus,	  the	  number	  of	  blue	  nucleated	  cells	  were	  counted	  in	  each	  well	  and	  the	  triplicate	  samples	  were	  averaged.	  Once	  averaged,	  the	  following	  formula	  was	  used	  to	  determine	  the	  number	  of	  infectious	  particles	  (IP)	  per	  mL	  of	  virus:	  
Formula	  1.	  Determine	  number	  of	  infectious	  particles	  per	  mL	  of	  virus	  
(#	  of	  blue	  nucleated	  cells)(dilution)(10)	  =	  #IP/mL	  
4.14.	  LUCIFERASE	  ASSAY	  	  
             In	  a	  6A well	  plate,	  500,000	  HeLa	  153	  cells	  were	  seeded	  and	  transfected	  (using	  Polyjet)	  with	  1µg	  of	  NRGNA 3’UTR	  plasmid	  (ActiveMotif).	  After	  18	  hours,	  the	  transfection	  media	  was	  removed	  and	  DA 10	  media	  was	  added	  to	  the	  cells.	  After	  adding	  the	  DA 10	  media,	  0.1	  MOI	  of	  HIVA 1	  chimeric	  reporter	  viruses	  (NLA YU2A env	  and	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NL 4A 3A GFP) were added to the cells and allowed	  to	  incubate	  for	  48	  hours.	  Forty-eight	  hours	  postA infection,	  the	  cells	  were	  lysed	  by	  adding	  100uL	  of	  LightSwitch	  Assay	  Solution	  (Switchgear)	  and	  incubated	  for	  30	  minutes	  at	  room	  temperature.	  After	  incubation,	  the	  cells	  were	  then	  moved	  to	  a	  black	  96A well	  plate	  (Nunc)	  and	  the	  plate	  was	  read	  on	  a	  luminometer	  (Veritas,	  Turner	  BioSystems)	  and	  the	  luciferase	  signal	  was	  recorded.	  	  
Figure	  4.	  Construct	  of	  NRGN-­‐3’UTR	  Luciferase	  Reporter	  Vector[93]	  
	  	  	  	  NRGN	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5.0	  RESULTS	  
5.1.	  AIM	  #1:	  CHARACTERIZATION	  OF	  ENDOGENOUS	  AND	  OVER-EXPRESSED	  NRGN	  
IN	  CELL	  LINES	  
5.1.1.	  Determine	  the	  endogenous	  expression	  of	  NRGN	  in	  neuronal	  cell	  lines	  by	  
immunoblot	  against	  NRGN	  (protein	  level)	  and	  qRT-PCR	  (RNA	  level)	  assays	  	  To	  study	  the	  degradation	  of	  NRGN	  within	  the	  neuronal	  cell	  lines,	  the	  level	  of	  endogenous	  expression	  of	  NRGN	  in	  the	  cells	  first	  I	  determined	  the	  level	  of	  NRGN	  RNA	  in	  neuronal	  cell	  lineages	  along	  with	  non-­‐neuronal	  lineage	  cells.	  We	  isolated	  RNA	  from	  A172,	  NT2,	  SH-­‐SY5Y,	  HeLa	  153,	  293T	  and	  PBMCs.	  The	  RNA	  was	  then	  transcribed	  to	  cDNA	  and	  qPCR	  was	  performed	  to	  measure	  mRNA	  NRGN	  expression	  (Figure	  3).	  Figure	  3	  shows	  that	  two	  of	  the	  three	  neuronal	  cell	  lines	  (NT2	  and	  SH-­‐SY5Y)	  have	  a	  high	  expression	  of	  NRGN	  and	  the	  A172	  cell	  lines	  has	  a	  low	  expression,	  which	  coincides	  with	  the	  literature	  that	  states	  this	  specific	  neuronal	  cell	  line	  hypo-­‐expresses	  NRGN[90].	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RT-PCR	  was	  performed	  for	  NRGN	  expression	  among	  the	  neuronal	  cell	  lines	  as	  well	  as	  control	  cell	  lines	  and	  the	  averages	  of	  5	   independent	  experiments	  (n=5)	  were	  collected	  and	  graphed.	  The	   low	  number	  of	  the	  average	  dCt	  corresponds	  to	  a	  high	  expression	  of	  NRGN.	  
Figure 5. Endogenous Expression of NRGN in neuronal cell lines by RT-PCR	  
After	  concluding	  that	  the	  neuronal	  cell	  lines	  of	  interest	  did	  express	  NRGN	  mRNA	  transcript,	  immunoblot	  was	  performed	  to	  determine	  protein	  expression	  using	  NRGN	  specific	  antibody	  (Figure	  4).	  Figure	  4	  exhibits	  that	  there	  is	  no	  NRGN	  present	  in	  the	  negative	  control	  (TZM)	  and	  also	  that	  there	  is	  very	  little	  NRGN	  expressed	  in	  A172	  cells,	  which	  further	  confirms	  the	  low	  mRNA	  expression	  of	  that	  particular	  neuronal	  cell	  line.	  Importantly,	  NT2	  neuronal	  cells,	  the	  differentiated	  hNT2	  neurons,	  as	  well	  as	  the	  SH-­‐SY5Y	  cells	  all	  express	  NRGN,	  as	  expected.	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Neuronal	  cell	  lines	  (A172,	  NT2,	  hNT2,	  and	  SH-SY5Y)	  and	  a	  control	  cell	  line	  (TZM)	  were	  lysed	  and	  the	  wholeA cell	  lysates	  were	  run	  on	  an	  SDS-PAGE	  gel	  and	  immunoblotted	  using	  anti-NRGN	  antibody	  to	  determine	  endogenous	  expression	  of	  NRGN	  within	  the	  neuronal	  cell	  lines	  of	  interest.	  The	  blot	  was	  then	  stripped	  and	  re-probed	  using	  an	  anti-α-Tubulin	  antibody	  to	  ensure	  equal	  loading	  of	  lysates.	  	  
Figure 6. Immunoblot of endogenous expression of NRGN in neuronal cell lines.


























(A)	  293T	  cells	  were	  transfected	  with	  pNRGN	  and	  the	  lysates	  were	  run	  on	  a	  SDS-PAGE	  gel	  and	  immunoblotted	  using	  the	  anti-NRGN	  antibody.	  (B)	  Cell	  lysates	  from	  293T	  cells	  transfected	  with	  pNRGN	  and	  pNRGN-FLAG	  and	  run	  on	  a	  SDS-PAGE	  gel	  and	  immunoblotted	  using	  an	  anti-FLAG	  antibody	  confirm	  successful	  cloning.	  	  
Figure 7. Confirmation of pNRGN and pNRGN-FLAG expression in 293T cell lysates. 
5.1.3.	  To	  determine	  the	  localization	  of	  endogenous	  NRGN	  in	  neuronal	  cells	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Figure	  8.	  Immunofluorescence	  staining	  of	  neuronal	  cell	  lines	  to	  determine 
localization of NRGN.	  
	  
(A)	  Immunofluoresence	  staining	  to	  determine	  localization	  of	  endogenous	  NRGN	  within	  neuronal	  cell	  lines	  of	  interest.	  (B)	  Immunofluoresence	  staining	  to	  determine	  localization	  of	  pNRGN	  transfected	  into	  neuronal	  cell	  lines	  of	  interest.	  Green	  =	  Antibody;	  Blue	  =	  DAPI;	  magnification:	  60x	  
5.1.4.	  Summary	  of	  AIM	  #1	  
           Neurogranin	  (NRGN)	  is	  specific	  to	  neuronal	  cell	  lines	  with	  the	  exception	  of	  293T	  cells.	  The	  A172	  cell	  line	  hypoA express	  NRGN,	  which	  can	  be	  seen	  by	  RTA PCR.	  A	  NRGNA FLAG	  plasmid	  was	  successfully	  cloned	  for	  use	  in	  immunofluorescence	  staining	  experiments	  for	  NRGN	  localization.	  	  	  
Untransfected 	  	  	  	  	  	  	  	  	  	  	  pNRGN-­‐FLAG
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5.2 	  AIM	  #2:	  EXAMINE	  THE	  EFFECT	  OF	  HIV-­‐1	  EXPOSURE/INFECTION	  ON	  NRGN	  IN	  
NEURONAL	  CELL	  LINES	  
5.2.1.	  To	  test	  whether	  neuronal	  cell	  lines	  express	  HIV-1	  receptor	  and	  co-








































































Control	  cell	  line	  ACH2	  and	  neuronal	  cell	  lines	  (A172,	  NT2,	  SHA SY5Y)	  were	  stained	  for	  the	  presence	  of	  the	   CD4	   receptor	   and	   the	   CXCR4	   and	   CCR5	   coA receptors	   necessary	   for	   HIV	   virus	   entry	   and	   HIVA 1	  infection.	  
Figure 9. Surface staining of neuronal cell lines to determine the presence of HIV-1 
receptor and co-receptors.   
5.2.2.	  Expose/infect	  neuronal	  cell	  lines	  with	  chimeric	  reporter	  viruses.	  After	  determining	  the	  presence	  of	  HIV-­‐1	  receptor	  CD4	  and	  co-­‐receptors	  CXCR4	  and	  CCR5	  using	  flow	  cytometry,	  the	  neuronal	  cell	  lines	  were	  then	  exposed	  to	  HIV-­‐1	  chimeric	  viruses,	  NL-­‐YU2-­‐env	  and	  NL43.	  48	  hours	  post	  exposure,	  the	  cells	  were	  harvested,	  lysed,	  and	  immunoblotted	  with	  antibodies	  specific	  for	  HIV-­‐1	  capsid	  protein	  p24,	  NRGN,	  and	  α-­‐tubulin.	  Figure	  10	  shows	  the	  effects	  of	  HIV-­‐1	  exposure	  on	  the	  neuronal	  cell	  lines.	  
Figure	  10.	  Immunoblot	  of	  neuronal	  cell	  lines	  after	  exposure	  to	  HIVV 1	  Chimeric 
viruses 


























































































5.2.3.	  Summary	  of	  AIM	  #2	  
           Based	  on	  the	  flow	  cytometry	  data,	  the	  neuronal	  cell	  lines	  have	  a	  very	  low	  percentage	  of	  HIV-1	  receptor,	  CD4.	  There	  is	  also	  a	  low	  presence	  of	  the	  HIV-1 co-receptors,	  CXCR4	  and	  
CCR5. With this information, the neuronal cell lines as well as a control cell liines were 
infected/exposed to HIV-1 chimeric viruses and the potential degradation of NRGN was 
analyzed via immunoblot. The results show that there is a low level of NRGN degradation 
in the SH-SY5Y cell line when exposed to the NL-(YU2)-Env chimeric virus.
5.3	  AIM	  #3:	  DETERMINE	  HOW	  NRGN	  IS	  DEGRADED	  BY	  HIV-­‐1	  
5.3.1.	  Using	  a	  3’UTR-NRGN-Luc	  transfected	  into	  HeLa	  cells	  to	  determine	  if	  
degradation	  occurs	  at	  the	  3’UTR	  of	  NRGN	  
            Previous	  microRNA	  (miRNA)	  data	  from	  our	  lab	  indicate	  that	  a	  number	  of	  miRNAs	  could	  potentially	  bind	  at	  the	  3’UTR	  of	  NRGN	  transcript	  upon	  HIVA 1	  infection	  and	  could	  possibly	  contribute	  to	  the	  degradation	  of	  the	  RNA	  transcript.	  A	  NRGNA 3’UTRALuciferace	  reporter	  construct	  was	  purchased	  from	  ActiveMotif	  and	  transfected	  into	  HeLa	  153	  cells	  to	  test	  this.	  PostA transfection	  (18	  hours),	  the	  cells	  were	  exposed	  to	  HIVA 1	  chimeric	  viruses.	  48	  hours	  postA infection,	  the	  cells	  were	  lysed	  using	  the	  luciferase	  assay	  buffer	  and	  luciferase	  activity	  was	  measured	  using	  a	  luminometer.	  Based	  on	  the	  luciferase	  activity	  data	  recorded	  (Figure	  11),	  there	  is	  no	  significant	  decrease	  in	  reporter	  activity	  indicating	  that	  miRNA	  binding	  to	  the	  3’UTR	  of	  NRGN	  is	  not	  the	  pathway.	  Infection/exposure	  of	  NLA YU2A env	  virus	  at	  a	  concentration	  of	  0.1	  MOI,	  did	  show	  a	  very	  high	  level	  of	  luciferase	  activity	  (above	  basal	  level),	  at	  multiple	  replicate	  experiments	  (4	  times).	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Luminescence	  activity	  was	  recorded	  from	  HeLa	  153	  cells	  transfected	  with	  the	  NRGN-3’UTR.	  The	  cells	  were	  infected	  with	  HIV-1	  chimeric	  viruses	  to	  determine	  if	  viral	  infection	  would	  have	  an	  effect	  on	  the	  3’UTR	  of	  NRGN.	  Infection	  with	  0.1µg	  NL-YU2-Env	  shows	  increased	  luminescence.	  (n=6)	  
Figure 11. NRGN 3’UTR Luciferase Reporter Assay 
5.3.2.	  Summary	  of	  AIM	  #3	  





















































6.0.	  DISCUSSION	  Since	  the	  first	  HIV-­‐1/AIDS	  cases	  have	  been	  reported,	  it	  has	  been	  about	  35	  years	  and	  the	  virus	  is	  still	  a	  great	  threat	  to	  the	  world	  population.	  Even	  with	  extensive	  research,	  it	  is	  not	  fully	  clear	  how	  the	  virus	  interacts	  with	  the	  host	  and	  establishes	  disease	  state.	  Additionally,	  it	  is	  unclear	  why	  certain	  individuals	  progress	  to	  HIV-­‐associated	  neurocognitive	  disorders	  (HAND)	  and	  others	  do	  not.	  With	  the	  advent	  of	  HAART,	  the	  progression	  of	  HIV-­‐1	  infected	  patients	  to	  HAD	  has	  greatly	  decreased,	  but	  many	  still	  progress	  to	  either	  ANI	  or	  MND[94-­‐96].	  The	  success	  of	  HAART	  in	  transforming	  the	  lives	  of	  HIV-­‐1-­‐infected	  individuals	  with	  access	  to	  these	  drugs	  by	  extending	  lives	  as	  well	  as	  the	  quality	  of	  life.	  This	  extension	  is	  overshadowed	  by	  the	  increasing	  risk	  of	  HAND[97].	  HIV-­‐1	  neuropathogenesis	  is	  still	  not	  fully	  understood.	  It	  is	  possible	  that	  there	  is	  an	  overlap	  of	  other	  neurodegenerative	  diseases	  that	  are	  already	  genetically	  present	  in	  infected	  individuals	  that	  share	  characteristics	  with	  HAND[98-­‐102].	  Neuroinflammation	  is	  a	  critical	  area	  to	  investigate	  as	  reflected	  by	  increased	  expression	  of	  inflammation	  or	  immune-­‐activation	  biomarkers	  in	  the	  brain,	  cerebrospinal	  fluid	  (CSF)	  and	  in	  some	  cases,	  plasma	  in	  individuals	  affected	  by	  HAND[103-­‐105].	  The	  key	  role	  for	  macrophages	  in	  HAND	  allows	  for	  studies	  of	  host	  genetic	  variation	  in	  HAND[101,	  106,	  107].	  	  	  Recent	  studies	  of	  HAND	  have	  focused	  on	  expression	  of	  microRNA	  (miRNA),	  small	  non-­‐coding	  RNA	  molecules	  that	  bind	  messenger	  RNA	  and	  regulate	  gene	  expression	  at	  the	  transcriptional	  or	  post-­‐transcriptional	  levels.	  miRNA	  expression	  studies	  conducted	  in	  cortical	  neurons	  exposed	  to	  viral	  proteins	  such	  as	  Tat	  and	  Vpr	  [108,	  109]	  or	  in	  tissue	  from	  individuals	  with	  HIV	  encephalitis	  (HIVE)	  have	  associated	  upregulation	  of	  the	  following	  classes	  of	  host	  miRNAs	  in	  HIVE:	  	  1)	  immune	  response	  and	  inflammation,	  2)	  nucleotide	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metabolism,	  3)	  cell	  cycle,	  4)	  oncogenesis	  (e.g.,	  miR-­‐21,	  which	  targets	  a	  neuronal	  transcription	  factor),	  and	  5)	  apoptosis.	  Downregulated	  miRNAs	  were	  involved	  in:	  1)	  inflammation,	  2)	  neuronal	  monoamine	  oxidase	  activity	  (possibly	  explaining	  the	  reduced	  dopaminergic	  activity	  in	  HAND),	  3)	  apoptosis,	  4)	  modulation	  of	  viral	  replication,	  5)	  mitochondrial	  function,	  and	  6)	  axonal	  guidance[108,	  110-­‐112].	  	  Merging	  short-­‐term	  memories	  into	  long-­‐term	  memory	  requires	  synaptic	  plasticity,	  described	  by	  altered	  gene	  expression	  and	  structural	  changes	  at	  the	  neuronal	  synapse[113].	  A	  recent	  study	  found	  that	  many	  synaptic	  plasticity	  genes	  in	  HIV-­‐infected	  astrocytes	  were	  downregulated,	  and	  there	  was	  an	  increased	  expression	  of	  pro-­‐apoptotic	  genes,	  compared	  to	  uninfected	  controls	  [113,	  114].	  These	  findings	  concluded	  that	  there	  was	  altered	  dendritic	  morphology	  and	  reduced	  dendritic	  spine	  density.	  	  Neurogranin	  (NRGN)	  is	  involved	  in	  synaptic	  plasticity	  and	  is	  a	  key	  component	  in	  the	  consolidation	  of	  short-­‐term	  memories	  to	  long-­‐term	  memory[15,	  115].	  Long-­‐term	  changes	  in	  synaptic	  plasticity	  depend	  on	  protein	  synthesis	  and	  transcription.	  NRGN	  is	  involved	  in	  synaptic	  plasticity	  through	  the	  regulation	  of	  CaM	  (calmodulin)-­‐mediated	  signaling[116,	  117].	  NRGN	  contains	  an	  IQ	  motif	  that	  allows	  for	  the	  binding	  to	  CaM	  and	  PA	  (phosphatidic	  acid)	  and	  can	  be	  phosphorylated	  by	  PKC	  (protein	  kinase	  C)[13,	  117,	  118].	  	  When	  NRGN	  is	  bound	  to	  CaM,	  it	  is	  shown	  to	  localize	  to	  the	  cytoplasm.	  When	  stimulated	  by	  PKC	  and	  unbound	  from	  CaM,	  NRGN	  shows	  a	  nuclear	  localization	  when	  expressed	  in	  cell	  lines[119].	  In	  our	  study,	  we	  saw	  that	  NRGN	  localized	  to	  the	  cytoplasm	  in	  the	  neuronal	  cell	  lines,	  which	  correlates	  with	  the	  literature	  that	  synaptic	  activity	  regulates	  its	  translocation	  to	  the	  nucleus[119].	  This	  is	  very	  likely	  due	  to	  its	  being	  bound	  to	  CaM.	  This	  could	  further	  be	  studied	  by	  immunofluorescence	  staining	  against	  CaM	  to	  determine	  if	  the	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NRGN	  is	  indeed	  bound,	  hence	  localizing	  to	  the	  cytoplasm.	  Another	  approach	  would	  be	  to	  stimulate	  the	  cells	  using	  PKC	  and	  performing	  subcellular	  fractionation	  and	  immunocytochemical	  techniques	  or	  live-­‐cell	  imaging	  to	  investigate	  the	  process	  of	  phosphorylation	  of	  NRGN	  upon	  stimulation	  of	  PKC	  and	  determining	  localization	  of	  the	  protein.	  	  NRGN	  is	  a	  neuron-­‐specific	  protein	  that	  is	  concentrated	  abundantly	  in	  the	  cerebral	  cortex,	  hippocampus,	  amygdala,	  basal	  ganglia,	  and	  hypothalamus[120].	  Because	  of	  this	  information,	  we	  chose	  293T	  cells	  as	  a	  negative	  control	  for	  our	  RT-­‐PCR	  experiments	  for	  NRGN	  mRNA	  expression.	  In	  our	  results	  we	  observed	  that	  293T	  cells	  do	  express	  our	  protein	  of	  interest	  and	  we	  found	  in	  the	  literature	  that	  293T	  cells	  express	  an	  array	  of	  neuron-­‐specific	  proteins[121].	  With	  this	  information,	  we	  used	  293T	  as	  a	  positive	  control	  and	  then	  chose	  HeLa	  153	  cells	  as	  our	  negative	  control,	  which	  we	  knew	  do	  not	  express	  NRGN.	  As	  expected,	  the	  results	  showed	  low	  expression	  of	  NRGN	  in	  the	  HeLa	  153	  cells	  and	  in	  the	  A172	  astrocytic	  cell	  line,	  which	  is	  known	  to	  hypoexpress	  the	  protein[90].	  As	  expected,	  we	  found	  high	  expression	  of	  NRGN	  in	  our	  other	  two	  neuronal	  cell	  lines,	  NT2	  and	  SH-­‐SY5Y.	  Neurons	  do	  not	  have	  the	  main	  surface	  receptor	  for	  HIV-­‐binding	  and	  entry	  into	  the	  cell,	  and	  therefore	  cannot	  directly	  be	  infected[122,	  123].	  In	  addition	  to	  the	  CD4	  receptor,	  chemokine	  receptors	  CXCR4	  and	  CCR5	  function	  as	  co-­‐receptors	  for	  HIV-­‐1	  entry	  into	  CD4+	  T	  cells.	  During	  the	  early	  stages	  of	  HIV-­‐1	  infection,	  viral	  isolates	  use	  CCR5	  for	  viral	  entry,	  and	  later	  isolates	  of	  the	  virus	  utilize	  CXCR4[124,	  125].	  To	  ensure	  the	  lack	  of	  CD4	  surface	  receptors	  and	  to	  investigate	  the	  presence	  of	  co-­‐receptors	  CXCR4	  and	  CCR5,	  we	  performed	  surface	  staining	  for	  the	  specific	  receptors	  and	  analyzed	  the	  cells	  using	  flow	  cytometry.	  As	  expected,	  the	  A172,	  NT2,	  and	  SH-­‐SY5Y	  cell	  lines	  had	  very	  low	  (almost	  negligible)	  presence	  of	  the	  CD4	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receptor	  and	  co-­‐receptors.	  The	  SH-­‐SY5Y	  cell	  line,	  however,	  did	  have	  a	  higher	  amount	  of	  the	  receptors	  than	  the	  other	  cell	  lines	  (~7%	  CD4+/CXCR4+	  and	  ~9%	  CD4+/CCR5+).	  However,	  it	  is	  not	  known	  whether	  primary	  neurons	  or	  differentiated	  neurons	  exhibit	  similar	  receptor	  expression	  levels	  in	  in	  vivo	  and	  there	  are	  reports	  supporting	  both	  the	  sides	  of	  the	  observation[126-­‐132].	  Which	  this	  information,	  next,	  we	  exposed	  the	  neuronal	  cell	  lines	  to	  the	  chimeric	  HIV-­‐1	  reporter	  viruses	  complemented	  with	  VSV-­‐Env,	  which	  does	  not	  need	  CD4	  or	  its	  co-­‐receptors	  for	  entry	  into	  the	  cell	  in	  order	  to	  determine	  if	  there	  was	  a	  possible	  degradation	  of	  NRGN	  within	  the	  cells.	  The	  results	  show	  a	  visible	  decrease	  in	  NRGN	  in	  the	  NT2	  and	  SH-­‐SY5Y	  cell	  lines	  when	  exposed	  to	  the	  NL-­‐YU2-­‐env	  chimeric	  virus	  complemented	  with	  VSV,	  which	  shows	  promise	  that	  HIV-­‐1	  infection	  does	  through	  some	  pathway	  degrade	  the	  protein.	  It	  is	  possible	  that	  because	  the	  YU2-­‐env	  virus	  was	  isolated	  from	  HIV-­‐1	  that	  was	  present	  in	  the	  brain	  while	  NL4-­‐3	  was	  not.	  Further	  experiments	  could	  involve	  the	  neuronal	  cell	  lines	  or	  cultivated	  neurons	  being	  exposed	  to	  media	  of	  infected	  macrophages	  and/or	  astrocytes	  to	  investigate	  cytokine/chemokine	  effects	  on	  the	  cells.	  Exploration	  of	  other	  co-­‐receptors	  that	  the	  virus	  could	  utilize	  that	  could	  be	  present	  on	  these	  cell	  lines	  would	  also	  be	  an	  avenue	  to	  pursue,	  since	  the	  viruses	  used	  in	  this	  experiment	  were	  complemented	  with	  VSV-­‐G-­‐Env.	  Previous	  miRNA	  data	  from	  Duskova	  et	  al[10]	  indicated	  a	  downregulation	  of	  NRGN	  at	  mRNA	  level,	  indicating	  that	  it	  could	  possibly	  be	  due	  to	  miRNA	  inhibition	  of	  mRNA	  translation	  into	  the	  NRGN	  protein	  at	  the	  3’UTR	  of	  RNA	  transcript.	  	  To	  explore	  this	  hypothesis,	  the	  3’UTR	  of	  NRGN	  in	  a	  luciferase	  reporter	  vector	  was	  transfected	  into	  the	  HeLa	  153	  cells	  and	  the	  cells	  were	  then	  infected	  with	  the	  chimeric	  reporter	  viruses	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complemented	  with	  VSV-­‐Env.	  The	  reporter	  data	  indicate	  that	  there	  is	  no	  significant	  effect	  by	  HIV-­‐1	  via	  the	  miRNA-­‐induced	  degradation	  and,	  therefore	  there	  must	  be	  a	  different	  pathway	  in	  which	  the	  protein	  is	  degraded.	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6.1.	  CONCLUSION	  
           This	  study	  sought	  to	  characterize	  and	  elucidate	  the	  role	  of	  NRGN	  in	  HIVA 1	  infected/exposed	  neuronal	  cell	  lines	  and	  to	  find	  support	  that	  there	  is	  a	  correlation	  between	  NRGN	  degradation	  caused	  by	  HIV-­‐1	  infection	  and	  HAND	  progression.	  In	  order	  to	  understand	  a	  role	  of	  NRGN	  in	  HIV-­‐1	  infection,	  neuronal	  cell	  lines	  expressing	  the	  protein	  were	  exposed	  to	  reporter	  viruses	  and	  degradation	  of	  the	  protein	  was	  analyzed	  via	  immunoblot.	  Results	  from	  this	  study	  suggest	  that	  NRGN	  does	  show	  degradation	  upon	  HIV-­‐1	  exposure	  –	  particularly	  in	  SH-­‐SY5Y	  neuronal	  cell	  lines	  –	  which	  can	  possibly	  be	  one	  of	  many	  contributing	  factors	  that	  can	  lead	  to	  a	  patient	  infected	  with	  HIV-­‐1	  progressing	  to	  HAND.	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7.0.	  FUTURE	  DIRECTIONS	  Something	  of	  interest	  in	  regards	  to	  NRGN	  is	  what	  exactly	  occurs	  once	  it	  dissociates	  from	  CaM	  and	  migrates	  towards	  the	  nucleus[75].	  It	  has	  yet	  to	  be	  determined	  the	  purpose	  NRGN	  serves	  asides	  from	  being	  bound	  to	  CaM	  and	  increasing	  intracellular	  Ca2+[67].	  It	  is	  possible	  that	  once	  this	  is	  determined,	  other	  pathways	  that	  NRGN	  as	  well	  as	  the	  other	  proteins	  in	  the	  calpacitin	  family	  is	  involved	  in	  can	  be	  elucidated.	  	  As	  a	  continuation	  of	  the	  current	  research,	  it	  would	  be	  interesting	  to	  be	  able	  to	  clone	  NRGN	  into	  a	  mCherry	  vector	  to	  visually	  investigate	  the	  possible	  degradation	  of	  NRGN	  in	  the	  presence	  of	  HIV-­‐1	  infection.	  The	  green	  fluorescence	  of	  the	  HIV-­‐1	  chimeric	  viruses,	  in	  theory,	  would	  become	  more	  prominent	  as	  the	  red	  fluorescence	  of	  the	  NRGN-­‐mCherry	  decreases	  showing	  a	  degradation	  of	  the	  protein	  in	  the	  presence	  of	  viral	  infection.	  	  Another	  avenue	  that	  can	  be	  explored	  are	  the	  ties	  between	  the	  hypothalamus-­‐pituitary-­‐thyroid	  pathway	  and	  its	  link	  to	  HIV-­‐1	  infection	  and	  its	  effect	  on	  the	  thyroid	  response	  element	  (TRE)	  present	  on	  neurogranin.	  Recent	  literature	  indicates	  that	  there	  is	  a	  link	  between	  hypothyroidism	  in	  HIV-­‐1	  infected	  individuals	  and	  a	  decrease	  in	  NRGN	  [11,	  133].	  There	  is	  no	  link	  of	  the	  decrease	  in	  NRGN	  and	  the	  progression	  to	  HAND,	  but	  it	  is	  something	  that	  should	  be	  thoroughly	  investigated.	  	  An	  area	  that	  should	  be	  thoroughly	  investigated	  is	  the	  3’UTR	  of	  NRGN	  and	  which,	  if	  any,	  microRNAs	  (miRNAs)	  affect	  the	  function	  of	  NRGN	  and	  can	  potentially	  lead	  to	  its	  degradation	  in	  HIV-­‐1	  infection.	  	  If	  there	  are	  specific	  miRNAs	  involved	  in	  the	  degradation	  of	  NRGN,	  those	  miRNAs	  can	  be	  targeted	  and	  can	  potentially	  protect	  against	  NRGN	  degradation.	  	  
42	  
8.0.	  PUBLIC	  HEALTH	  SIGNIFICANCE	  The	  public	  health	  significance	  of	  this	  project	  is	  that	  in	  determining	  the	  underlying	  contributors	  to	  the	  degradation	  of	  cognition	  in	  HIV-­‐1	  infected	  individuals	  that	  progress	  to	  HAND,	  treatments	  can	  be	  developed	  to	  combat	  the	  effects	  on	  HIV-­‐1	  on	  proteins	  and	  cells	  pertinent	  to	  normal	  brain	  function.	  In	  fully	  elucidating	  the	  complete	  role	  of	  NRGN	  in	  the	  Ca2+/CaM	  pathway,	  the	  PKC	  pathway	  and	  its	  role	  in	  the	  HPT-­‐axis,	  it	  can	  be	  determined	  if	  NRGN	  degradation	  is	  a	  key	  factor	  contributing	  to	  HAND	  or	  one	  of	  many	  side	  effects	  of	  a	  larger	  dysregulation	  in	  the	  brain	  caused	  by	  HIV-­‐1	  infection.	  With	  the	  advent	  of	  HAART,	  HIV-­‐1	  infected	  individuals	  are	  able	  to	  live	  longer,	  but	  the	  effect	  of	  HAART	  on	  HAND	  is	  not	  enough	  to	  removed	  cognitive	  degeneration	  altogether[97].	  Though	  there	  is	  a	  decrease	  in	  individuals	  that	  progress	  to	  HAD,	  many	  do	  experience	  the	  earlier	  stages	  of	  HAND	  (ANI	  and	  MND)	  and	  there	  is	  currently	  no	  way	  to	  determine	  which	  of	  the	  HIV-­‐1	  infected	  on	  HAART	  will	  or	  will	  not	  experience	  cognitive	  degeneration.	  	  	  By	  investigating	  NRGN,	  which	  is	  currently	  being	  used	  a	  biomarker	  for	  Alzheimer’s	  Disease	  (AD)[82],	  it	  is	  possible	  that	  it	  or	  other	  proteins	  shown	  to	  be	  degraded	  in	  patients	  with	  a	  form	  of	  HAND	  can	  be	  used	  as	  an	  early	  detection	  tool	  to	  determine	  if	  an	  infected	  individual	  could	  potentially	  progress	  to	  HAND	  and	  can	  allow	  researchers	  to	  develop	  a	  treatment	  against	  such	  progression.	  If	  such	  a	  treatment	  is	  developed,	  not	  only	  can	  it	  be	  used	  in	  conjunction	  with	  HAART	  to	  extend	  the	  lives	  of	  individuals	  living	  with	  HIV-­‐1	  but	  to	  also	  preserve	  their	  cognition	  and	  lead	  to	  an	  even	  small	  incidence	  of	  HAND.	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